Ergomed Plc (LON:ERGO) has now licensed its anti-cancer drug Zoptrex in the important markets of China, Israel, Taiwan and Southeast Asia.
Its Canada and US-listed partner Aeterna Zentaris Inc. (NASDAQ:AEZS, TSX:AEZ) signed an exclusive deal with affiliates of Orient EuroPharma for the compound, initially for endometrial cancer for Taiwan and nine countries in Southeast Asia at the beginning of July.
At the end of the same month, and exclusive licence agreement was struck with Rafa Laboratories for Israel and the Palestine Territories.
These two agreements follow the 2014 licence agreement with Sinopharm A-Think Pharmaceuticals Co and Ergomed will receive a portion of all revenues generated.
Endometrial cancer is one that affects the lining of the womb and the drug is currently in a fully-enrolled Phase 3 clinical trial for this type of cancer, which is now expected to complete by the end of the year.
Results will follow in early 2017, and if these are positive, a new drug application for Zoptrex will be filed in the first half of 2017.
Dr Miroslav Reljanovic, Ergomed chief executive, said: "We are delighted that our partner, Aeterna Zentaris has now licensed Zoptrex in the important markets of China, Israel, Taiwan and Southeast Asia.
"In line with our strategy at IPO, these deals mark an important milestone in our co-development partnership with Aeterna Zentaris and demonstrate the value of our hybrid business model."
In-depth - Ergomed looking to fill in the gaps after milestone year
Watch - Ergomed expanding via earnings-enhancing acquisitions